Skip to Content
Merck
All Photos(3)

Documents

F7129

Sigma-Aldrich

5-Fluorocytosine

nucleoside analog

Synonym(s):

4-amino-5-fluoro-2(1H)-pyrimidinone, Flucytosine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C4H4FN3O
CAS Number:
Molecular Weight:
129.09
Beilstein:
127285
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.32

Quality Level

Assay

≥99% (TLC)

mp

298-300 °C (dec.) (lit.)

antibiotic activity spectrum

fungi

Mode of action

DNA synthesis | interferes
protein synthesis | interferes

storage temp.

2-8°C

SMILES string

NC1=NC(=O)NC=C1F

InChI

1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)

InChI key

XRECTZIEBJDKEO-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Chemical structure: nucleoside

Application

Used in studies on TMP biosynthesis.

Biochem/physiol Actions

Nucleoside analog that has antifungal activities. 5-FC is deaminated by cytosine deaminase to product 5-fluorouracil, resulting in RNA miscoding. 5-Fluorocytosine inhibits DNA and RNA synthesis and interferes with ribosomal protein synthesis.

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Annemarie E Brouwer et al.
Antimicrobial agents and chemotherapy, 51(3), 1038-1042 (2006-12-30)
In a randomized controlled trial of amphotericin B-based therapy for human immunodeficiency virus (HIV)-associated cryptococcal meningitis in Thailand, we also compared the mycological efficacy, toxicity, and pharmacokinetics of oral versus intravenous flucytosine at 100 mg/kg of body weight/day for the
A Gomez-Lopez et al.
Antimicrobial agents and chemotherapy, 52(4), 1506-1509 (2008-02-21)
We describe the prevalences and susceptibility profiles of two recently described species, Candida metapsilosis and Candida orthopsilosis, related to Candida parapsilosis in candidemia. The prevalences of these species (1.7% for C. metapsilosis and 1.4% for C. orthopsilosis) are significant. Differences
Francesco Imperi et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(18), 7458-7463 (2013-04-10)
Although antibiotic resistance represents a public health emergency, the pipeline of new antibiotics is running dry. Repurposing of old drugs for new clinical applications is an attractive strategy for drug development. We used the bacterial pathogen Pseudomonas aeruginosa as a
P Francis et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 15(6), 1003-1018 (1992-12-01)
Flucytosine is an antifungal agent useful in combination with amphotericin B in the treatment of several deeply invasive mycoses. The potentially dose-limiting, hematologic, gastrointestinal, and hepatic toxicities of flucytosine lead to a reluctance to use it in myelosuppressed patients. To
Hong Jun Lee et al.
Cancer letters, 335(1), 58-65 (2013-02-09)
Prostate cancer is the most common malignancy among men. Prostate cancer-related deaths are largely attributable to the development of hormone resistance in the tumor. No effective chemotherapy has yet been developed for advanced prostate cancer. It is desirable if a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service